New transplant cocktail aims to tame blood cancer without severe side effects
NCT ID NCT07565220
First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early-stage trial is testing a new combination of chemotherapy drugs (thiotepa, busulfan, and fludarabine) followed by a stem cell transplant for people with certain blood cancers like leukemia and myelodysplastic syndrome. The goal is to see if this approach can reduce the dose of a post-transplant drug (cyclophosphamide) that helps prevent graft-versus-host disease, a serious complication. The study will enroll 48 adults aged 18-70 who are candidates for a stem cell transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Thiotepa, Fludarabine, Busulfan (chemotherapy drugs) and a stem cell transplant
What this could lead to
If successful, this could lead to a safer and more effective transplant procedure for people with blood cancers, reducing the risk of graft-versus-host disease and relapse.
What could go wrong
This is an early Phase 1 trial with only 48 participants, so the results may not apply to everyone. The treatment involves strong chemotherapy and carries risks like infection, organ damage, and graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UMPC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact